SG10201403147SA - Diketopiperazine microparticles with defined isomer contents - Google Patents
Diketopiperazine microparticles with defined isomer contentsInfo
- Publication number
- SG10201403147SA SG10201403147SA SG10201403147SA SG10201403147SA SG10201403147SA SG 10201403147S A SG10201403147S A SG 10201403147SA SG 10201403147S A SG10201403147S A SG 10201403147SA SG 10201403147S A SG10201403147S A SG 10201403147SA SG 10201403147S A SG10201403147S A SG 10201403147SA
- Authority
- SG
- Singapore
- Prior art keywords
- diketopiperazine microparticles
- isomer contents
- defined isomer
- contents
- diketopiperazine
- Prior art date
Links
- 239000011859 microparticle Substances 0.000 title 1
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18677909P | 2009-06-12 | 2009-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201403147SA true SG10201403147SA (en) | 2014-10-30 |
Family
ID=43306942
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201706995VA SG10201706995VA (en) | 2009-06-12 | 2010-06-11 | Diketopiperazine microparticles with defined isomer contents |
SG2013076096A SG195546A1 (en) | 2009-06-12 | 2010-06-11 | Diketopiperazine microparticles with defined isomer contents |
SG10201403147SA SG10201403147SA (en) | 2009-06-12 | 2010-06-11 | Diketopiperazine microparticles with defined isomer contents |
SG2011091410A SG176778A1 (en) | 2009-06-12 | 2010-06-11 | Diketopiperazine microparticles with defined isomer contents |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201706995VA SG10201706995VA (en) | 2009-06-12 | 2010-06-11 | Diketopiperazine microparticles with defined isomer contents |
SG2013076096A SG195546A1 (en) | 2009-06-12 | 2010-06-11 | Diketopiperazine microparticles with defined isomer contents |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2011091410A SG176778A1 (en) | 2009-06-12 | 2010-06-11 | Diketopiperazine microparticles with defined isomer contents |
Country Status (17)
Country | Link |
---|---|
US (1) | US8227409B2 (en) |
EP (2) | EP3556356B1 (en) |
JP (2) | JP5859432B2 (en) |
KR (1) | KR101782174B1 (en) |
CN (1) | CN102458371B (en) |
AR (1) | AR077087A1 (en) |
AU (1) | AU2010259939B2 (en) |
BR (1) | BRPI1010722B1 (en) |
CA (1) | CA2765156C (en) |
ES (2) | ES2880102T3 (en) |
IL (1) | IL216910A (en) |
MX (1) | MX2011013313A (en) |
MY (1) | MY172858A (en) |
RU (1) | RU2490026C1 (en) |
SG (4) | SG10201706995VA (en) |
TW (1) | TWI513692B (en) |
WO (1) | WO2010144785A2 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9006175B2 (en) * | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
CA2479751C (en) | 2002-03-20 | 2008-06-03 | Trent Poole | Inhalation apparatus |
US20070027063A1 (en) * | 2004-01-12 | 2007-02-01 | Mannkind Corporation | Method of preserving the function of insulin-producing cells |
ES2385934T3 (en) | 2004-08-20 | 2012-08-03 | Mannkind Corporation | CATALYSIS OF THE SYNTHESIS OF DICETOPIPERAZINA. |
KR101644250B1 (en) | 2004-08-23 | 2016-07-29 | 맨카인드 코포레이션 | Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery |
DK1928423T3 (en) | 2005-09-14 | 2016-02-29 | Mannkind Corp | A method for drug formulation based on increasing the affinity of the active substances to the crystalline microparticle surfaces |
US8039431B2 (en) | 2006-02-22 | 2011-10-18 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
ES2302448B1 (en) * | 2006-10-20 | 2009-05-08 | Vodafone España, S.A. | SYSTEM AND METHOD OF DISSEMINATION OF AREA INFORMATION IN LOCAL ENVIRONMENTS OF REDUCED SIZE WITHIN A MOBILE COMMUNICATIONS CELL SYSTEM. |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
AU2009257311B2 (en) | 2008-06-13 | 2014-12-04 | Mannkind Corporation | A dry powder inhaler and system for drug delivery |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
TWI532497B (en) | 2008-08-11 | 2016-05-11 | 曼凱公司 | Use of ultrarapid acting insulin |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
JP5667095B2 (en) | 2009-03-11 | 2015-02-12 | マンカインド コーポレイション | Apparatus, system and method for measuring inhaler resistance |
CA2764505C (en) | 2009-06-12 | 2018-09-25 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
RU2571331C1 (en) | 2010-06-21 | 2015-12-20 | Маннкайнд Корпорейшн | Systems and methods for dry powder drug delivery |
CN103108650A (en) | 2010-08-25 | 2013-05-15 | Atyr医药公司 | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases |
CN105667994B (en) | 2011-04-01 | 2018-04-06 | 曼金德公司 | Blister package for pharmaceutical kit |
US9452219B2 (en) | 2011-06-02 | 2016-09-27 | University Of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
CA2852536A1 (en) | 2011-10-24 | 2013-05-02 | Mannkind Corporation | Methods and compositions for treating pain |
US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
ES2754388T3 (en) * | 2013-03-15 | 2020-04-17 | Mannkind Corp | Compositions and methods of microcrystalline dicetopiperazine |
US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
EP3030294B1 (en) | 2013-08-05 | 2020-10-07 | MannKind Corporation | Insufflation apparatus |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
US9968125B2 (en) | 2015-01-09 | 2018-05-15 | Philip Morris Products S.A. | Nicotine—diketopiperazine microparticle formulations and methods of making the same |
PT108368B (en) * | 2015-03-31 | 2018-11-05 | Hovione Farm S A | Continuous production of particles |
IL260823B1 (en) * | 2016-01-29 | 2024-04-01 | Mannkind Corp | Dry powder inhaler |
US20210299156A1 (en) | 2020-03-28 | 2021-09-30 | Qualigen Inc. | Methods of inhibiting or treating coronavirus infection, and methods for delivering an anti-nucleolin agent |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT83613B (en) | 1985-10-28 | 1988-11-21 | Lilly Co Eli | Process for the selective chemical removal of a protein amino-terminal residue |
US5693338A (en) * | 1994-09-29 | 1997-12-02 | Emisphere Technologies, Inc. | Diketopiperazine-based delivery systems |
US6331318B1 (en) * | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
US5352461A (en) * | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
US5888477A (en) * | 1993-01-29 | 1999-03-30 | Aradigm Corporation | Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin |
US5506203C1 (en) * | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
US5547929A (en) * | 1994-09-12 | 1996-08-20 | Eli Lilly And Company | Insulin analog formulations |
US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
ATE270097T1 (en) | 1998-04-09 | 2004-07-15 | Celanese Ventures Gmbh | PARTICULAR ACTIVE CARRIER FOR PULMONARY APPLICATION |
PT1196430E (en) * | 1999-06-29 | 2012-04-18 | Mannkind Corp | Purification and stabilization of peptide and protein pharmaceutical agents |
US9006175B2 (en) * | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
US7464706B2 (en) * | 1999-07-23 | 2008-12-16 | Mannkind Corporation | Unit dose cartridge and dry powder inhaler |
CA2479751C (en) * | 2002-03-20 | 2008-06-03 | Trent Poole | Inhalation apparatus |
US7625865B2 (en) * | 2004-03-26 | 2009-12-01 | Universita Degli Studi Di Parma | Insulin highly respirable microparticles |
ES2385934T3 (en) | 2004-08-20 | 2012-08-03 | Mannkind Corporation | CATALYSIS OF THE SYNTHESIS OF DICETOPIPERAZINA. |
KR101644250B1 (en) | 2004-08-23 | 2016-07-29 | 맨카인드 코포레이션 | Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery |
CA2592776A1 (en) * | 2005-01-10 | 2006-08-17 | Mannkind Corporation | Methods and compositions for minimizing accrual of inhalable insulin in the lungs |
DK1928423T3 (en) | 2005-09-14 | 2016-02-29 | Mannkind Corp | A method for drug formulation based on increasing the affinity of the active substances to the crystalline microparticle surfaces |
US8039431B2 (en) | 2006-02-22 | 2011-10-18 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
AU2007238000B2 (en) | 2006-04-14 | 2013-01-17 | Mannkind Corporation | Glucagon-like peptide 1(GLP-1) pharmaceutical formulations |
AU2008316634B2 (en) * | 2007-10-24 | 2014-02-27 | Mannkind Corporation | Method of preventing adverse effects by GLP-1 |
WO2009055742A2 (en) * | 2007-10-24 | 2009-04-30 | Mannkind Corporation | Delivery of active agents |
AU2009257311B2 (en) * | 2008-06-13 | 2014-12-04 | Mannkind Corporation | A dry powder inhaler and system for drug delivery |
-
2010
- 2010-06-11 ES ES19175215T patent/ES2880102T3/en active Active
- 2010-06-11 WO PCT/US2010/038287 patent/WO2010144785A2/en active Application Filing
- 2010-06-11 CA CA2765156A patent/CA2765156C/en active Active
- 2010-06-11 SG SG10201706995VA patent/SG10201706995VA/en unknown
- 2010-06-11 RU RU2012100785/15A patent/RU2490026C1/en active
- 2010-06-11 EP EP19175215.3A patent/EP3556356B1/en active Active
- 2010-06-11 ES ES10724973T patent/ES2751107T3/en active Active
- 2010-06-11 BR BRPI1010722 patent/BRPI1010722B1/en active IP Right Grant
- 2010-06-11 SG SG2013076096A patent/SG195546A1/en unknown
- 2010-06-11 JP JP2012515175A patent/JP5859432B2/en active Active
- 2010-06-11 CN CN201080026117.7A patent/CN102458371B/en active Active
- 2010-06-11 MX MX2011013313A patent/MX2011013313A/en active IP Right Grant
- 2010-06-11 AU AU2010259939A patent/AU2010259939B2/en active Active
- 2010-06-11 MY MYPI2011006016A patent/MY172858A/en unknown
- 2010-06-11 US US12/813,839 patent/US8227409B2/en active Active
- 2010-06-11 TW TW099119045A patent/TWI513692B/en active
- 2010-06-11 SG SG10201403147SA patent/SG10201403147SA/en unknown
- 2010-06-11 KR KR1020127000804A patent/KR101782174B1/en active IP Right Grant
- 2010-06-11 EP EP10724973.2A patent/EP2440186B1/en active Active
- 2010-06-11 SG SG2011091410A patent/SG176778A1/en unknown
- 2010-06-14 AR ARP100102093A patent/AR077087A1/en not_active Application Discontinuation
-
2011
- 2011-12-12 IL IL216910A patent/IL216910A/en active IP Right Grant
-
2015
- 2015-09-07 JP JP2015176164A patent/JP6101326B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201403147SA (en) | Diketopiperazine microparticles with defined isomer contents | |
IL216911A0 (en) | Diketopiperazine microparticles with defined specific surface areas | |
GB2457110B (en) | Sifting containers | |
IL215191A0 (en) | Improved containers | |
PL2323911T3 (en) | Large container | |
TWI561435B (en) | Bottle | |
ZA201209432B (en) | Oval-neck bottle | |
EP2623427A4 (en) | Bottle | |
EP2623426A4 (en) | Bottle | |
GB201116695D0 (en) | Container assembly | |
SI2390185T1 (en) | Container transporter | |
PL2328814T3 (en) | Large container | |
EP2317989A4 (en) | Microparticles | |
GB2478109B (en) | Containers | |
GB201120324D0 (en) | Improved containers and assembly thereof | |
PL2216467T3 (en) | Large container | |
AP2008000293S (en) | Pet bottle design | |
GB201019900D0 (en) | Improved containers and assembly thereof | |
AU337552S (en) | Bottle | |
TWM389080U (en) | Bicycle hanging container | |
AU335071S (en) | Bottle | |
GB201002584D0 (en) | Improved Bottle | |
AU334039S (en) | Bottle | |
AP2008000287S (en) | Bottle Design | |
PL119358U1 (en) | Bottle |